See more : PT Bank Syariah Indonesia Tbk (BRIS.JK) Income Statement Analysis – Financial Results
Complete financial analysis of YAKUODO HOLDINGS Co., Ltd. (7679.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of YAKUODO HOLDINGS Co., Ltd., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Personalis, Inc. (PSNL) Income Statement Analysis – Financial Results
- Changjiang & Jinggong Steel Building (Group) Co., Ltd (600496.SS) Income Statement Analysis – Financial Results
- Hubei Dinglong CO.,Ltd. (300054.SZ) Income Statement Analysis – Financial Results
- Expand Energy Corporation (EXE) Income Statement Analysis – Financial Results
- Fintech Ecosystem Development Corp. (FEXD) Income Statement Analysis – Financial Results
YAKUODO HOLDINGS Co., Ltd. (7679.T)
About YAKUODO HOLDINGS Co., Ltd.
YAKUODO HOLDINGS Co., Ltd., through its subsidiaries, engages in the management of drug stores in Japan. It operates 358 stores. The company was founded in 1978 and is headquartered in Morioka, Japan.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 142.24B | 128.79B | 120.31B | 110.54B | 102.02B | 91.81B | 83.10B | 74.91B | 66.94B |
Cost of Revenue | 114.38B | 100.54B | 93.07B | 84.88B | 78.59B | 72.32B | 65.43B | 59.38B | 53.33B |
Gross Profit | 27.86B | 28.25B | 27.24B | 25.66B | 23.43B | 19.49B | 17.67B | 15.54B | 13.60B |
Gross Profit Ratio | 19.59% | 21.93% | 22.64% | 23.21% | 22.96% | 21.23% | 21.27% | 20.74% | 20.32% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 22.65B | 20.79B | 19.93B | 17.72B | 16.80B | 15.23B | 13.86B | 12.18B | 10.92B |
Other Expenses | 0.00 | 374.00M | 361.00M | 335.00M | 370.00M | -369.00M | -286.00M | -167.00M | -31.00M |
Operating Expenses | 22.65B | 23.59B | 23.19B | 20.68B | 19.51B | 15.60B | 14.15B | 12.35B | 10.95B |
Cost & Expenses | 137.03B | 124.13B | 116.26B | 105.56B | 98.10B | 87.92B | 79.57B | 71.73B | 64.29B |
Interest Income | 17.00M | 18.00M | 20.00M | 22.00M | 23.00M | 11.00M | 26.00M | 28.00M | 32.00M |
Interest Expense | 48.00M | 38.00M | 31.00M | 28.00M | 14.00M | 14.00M | 15.00M | 20.00M | 25.00M |
Depreciation & Amortization | 2.82B | 2.80B | 2.59B | 2.39B | 2.22B | 1.96B | 1.73B | 1.60B | 1.43B |
EBITDA | 8.16B | 7.56B | 6.67B | 7.10B | 6.55B | 5.85B | 5.26B | 4.78B | 4.08B |
EBITDA Ratio | 5.74% | 6.10% | 5.83% | 6.98% | 6.40% | 6.37% | 6.33% | 6.38% | 6.10% |
Operating Income | 5.21B | 4.66B | 4.04B | 4.98B | 3.91B | 3.89B | 3.53B | 3.19B | 2.65B |
Operating Income Ratio | 3.66% | 3.62% | 3.36% | 4.50% | 3.84% | 4.23% | 4.25% | 4.25% | 3.96% |
Total Other Income/Expenses | 81.00M | 62.00M | -1.00M | -295.00M | 398.00M | 351.00M | 543.00M | 286.00M | 199.00M |
Income Before Tax | 5.29B | 4.72B | 4.04B | 4.68B | 4.31B | 4.24B | 4.07B | 3.47B | 2.85B |
Income Before Tax Ratio | 3.72% | 3.67% | 3.36% | 4.24% | 4.23% | 4.62% | 4.90% | 4.63% | 4.26% |
Income Tax Expense | 1.47B | 1.48B | 1.08B | 1.39B | 1.19B | 1.29B | 1.15B | 1.14B | 1.06B |
Net Income | 3.83B | 3.24B | 2.96B | 3.29B | 3.12B | 2.95B | 2.92B | 2.33B | 1.79B |
Net Income Ratio | 2.69% | 2.52% | 2.46% | 2.98% | 3.06% | 3.21% | 3.51% | 3.12% | 2.67% |
EPS | 195.20 | 164.92 | 150.15 | 166.66 | 158.15 | 149.19 | 147.82 | 118.23 | 90.52 |
EPS Diluted | 195.20 | 164.92 | 150.15 | 166.66 | 158.15 | 149.19 | 147.82 | 118.23 | 90.52 |
Weighted Avg Shares Out | 19.59M | 19.65M | 19.74M | 19.74M | 19.74M | 19.74M | 19.74M | 19.74M | 19.74M |
Weighted Avg Shares Out (Dil) | 19.59M | 19.65M | 19.74M | 19.74M | 19.74M | 19.74M | 19.74M | 19.74M | 19.74M |
Source: https://incomestatements.info
Category: Stock Reports